New Mouth-Dissolving pastilles tested in fight against aggressive brain cancer
NCT ID NCT06011109
Summary
This study is testing whether adding a new experimental medicine called APG-157, taken as dissolving pastilles in the mouth, can help control aggressive brain tumors (high-grade glioma) that have returned after previous treatment. The APG-157 pastilles are given alongside the standard drug bevacizumab. Researchers want to see if this combination helps patients live longer without their cancer getting worse and improves their quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Nebraska Medical Center
RECRUITINGOmaha, Nebraska, 68198, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.